WASHINGTON (CBS.MW) -- Mylan Laboratories , responding to the latest in a series of letters from investor Carl Icahn, reasserted its position that acquiring King Pharmaceuticals is in the long-term ...

Case Name: Bausch Health Ireland Ltd. v. Mylan Labs. Ltd., No. 21-10403 (SRC) (JSA), 2022 WL 683084 (D.N.J. Mar. 8, 2022) (Chesler, J.) Drug Product and Patent(s)-in ...

Mylan Laboratories said on Monday it agreed to acquire troubled drugmaker King Pharmaceuticals Inc. for about $4 billion, adding patent-protected brand drugs to Mylan’s generic-drug offerings.

Mylan appealed from a Patent Trial and Appeal Board (Board) discretionary denial of institution of an inter partes review (IPR) proceeding. The Board declined to institute Mylan’s IPR under NHK-Fintiv ...

NEW YORK, Feb 1 (Reuters) - Mylan Laboratories Inc. said on Thursday that quarterly profit more than doubled, and reported better-than-expected sales, helped by its generic version of the Ditropan XL ...

Drugmaker Mylan Laboratories said it lost $71.3 million ($0.31/share) in FQ4, vs. a $57.7 million profit a year ago, but that its adjusted profit of $0.47/share (ex-acquisition costs) beat its ...

Please provide your email address to receive an email when new articles are posted on . Mylan Pharmaceuticals has issued a voluntary recall of one batch of its 100 units/mL insulin glargine injection ...

Billionaire investor Carl Icahn has dropped his $5.39 billion offer to buy Mylan Laboratories Inc. and tendered his shares after regulators opened an investigation of a Mylan pain patch that was ...

A recently issued US Food and Drug Administration (FDA) warning letter escalated previously observed issues around quality control at Mylan Pharmaceuticals’ manufacturing facility in Morgantown, WV, ...

TEL AVIV (MarketWatch) -- Mylan Laboratories Inc., the Pittsburgh pharmaceutical producer, said it definitively agreed to pay 4.9 billion euros, or about $6.7 billion, for the generic-drug operations ...

PITTSBURGH (AP) -- One of the world's largest generic drug makers, Mylan Laboratories Inc., will buy King Pharmaceuticals Inc. for $4 billion in stock as Mylan makes a stronger foray into the branded ...